Mesenchymal Cell News 11.02 January 22, 2019 | |
| |
TOP STORYSoluble Matrix Protein Is a Potent Modulator of Mesenchymal Stem Cell Performance Researchers showed that tropoelastin alone drove MSC proliferation and phenotypic maintenance, akin to the synergistic effects of potent growth factors such as insulin-like growth factor 1 and basic fibroblast growth factor. In addition, tropoelastin functionally surpassed these growth factors, as well as fibronectin, in allowing substantial media serum reduction without loss of proliferative potential. [Proc Natl Acad Sci USA] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)IN VITROInvestigators evaluated the effects of hypercapnic acidosis on inflammatory response and reparative potential of the primary human small airway epithelial and lung microvasculature endothelial cells as well as on the capacity of bone marrow-derived MSCs to promote wound healing in vitro. [FASEB J] Abstract Enhanced expression of miR-181a in immortalized bone marrow derived stromal cell (iBMSC) and patient adipose derived stromal cells produced a robust increase in adipogenesis through the direct targeting of the circadian factor period circadian regulator 3 (PER3). Scientists showed that knocking down endogenous miR-181a expression in iBMSC has a profound inhibitory effect on iBMSC adipogenesis through its regulation of PER3. [Sci Rep] Full Article The overexpression of OCT4 promoted proliferation, cell cycle progression, and osteogenic differentiation capacity of human hair follicle MSCs (hHFMSCs). The overexpression of p21 abrogated the proliferation and osteogenic differentiation capacity of hHFMSCsOCT4 and promoted cell senescence. [Stem Cell Res Ther] Full Article Exosome-treated bone marrow MSCs (BM-MSCs) exhibited reduced oxidative stress, accelerated DNA damage repair, and reduced proliferation inhibition and cell senescence-associate protein expression compared with BM-MSCs that exclusively received irradiation. Following irradiation, exosomes promoted β-catenin expression in BM-MSCs and restored the balance between adipogenic and osteogenic differentiation. [Stem Cell Res Ther] Full Article MicroRNA-29b Regulates Hypertrophy of Murine Mesenchymal Stem Cells Induced toward Chondrogenesis miR-29b expression was assessed during murine MSC (mMSCs) chondrogenesis. To detect whether miR-29b affected chondrocyte hypertrophy, the mMSCs induced toward chondrogenesis were transfected with miR-29b or its antisense inhibitor (antagomiR-29b). Finally, the differential effects of antagomiR-29b on chondrocytes at different differentiation stages were evaluated by loss-of-function experiments. [J Cell Biochem] Abstract IN VIVOTo assess the effects of polyethylene glycol modified platelet-rich plasma (PRP) hydrogels on cells, PRP solutions were seeded with human adipose-derived stem cells (ASCs) prior to gelation. Using a rat skin excision model, wounds treated with PRP + ASC hydrogels increased the number of vessels in the wound by day eight compared to controls. [Acta Biomater] Abstract | Graphical Abstract Researchers demonstrated that heparan sulfate mimetic injections that restore the extracellular matrix network and enhance the biological activity of growth factors, associated with local injection of MSC protected in a hydrogel, that increase cell engraftment and cell survival, improved the therapeutic benefit of MSC treatment in two animal models relevant of human pathology. [Sci Rep] Full Article To dissect the contribution of circadian molecular clocks in individual bone cell types, the authors generated mice with conditional deletion of brain and muscle arntl-like 1 in osteoclasts and in mesenchymal cells of the limbs. [Bone] Abstract Investigators showed that MSCs elicited protection to acute intestinal inflammation with gain of weight, improvement in the clinical disease score and expressive reduction in the mortality rate of treated mice. [Clin Exp Immunol] Abstract Subscribe to one of our other 19 science newsletters such as ESC & iPSC News & Cell Therapy News. | |
| |
REVIEWSThe authors review the nature, clinical trials and patents involving the use of adipose-derived MSCs (ASCs) in musculoskeletal disorders. They describe ASCs’ isolation, culture and differentiation in vivo and in vitro, advances on ASCs’ applications in bone, cartilage, muscle and tendon repair, and patents involving the use of ASCs. [Expert Opin Biol Ther] Abstract Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field. | |
| |
INDUSTRY NEWSLilly Reports Results of Phase III Soft Tissue Sarcoma Study of LARTRUVO® Eli Lilly and Company reported that the results of ANNOUNCE, the Phase III study of LARTRUVO®, in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma, did not confirm the clinical benefit of LARTRUVO in combination with doxorubicin as compared to doxorubicin, a standard of care treatment. [Eli Lilly and Company] Press Release Cellular Biomedicine Group, Inc. announced that its off-the-shelf allogeneic adipose-derived mesenchymal progenitor cell AlloJoin® therapy for KOA has been approved as the first stem cell KOA drug application in China for a Phase II clinical trial. [Cellular Biomedicine Group, Inc.] Press Release BrainStorm Granted Additional Patent for NurOwn® in Israel BrainStorm Cell Therapeutics Inc. announced that the Israel Patent Office has granted an additional patent titled “Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors.” [BrainStorm Cell Therapeutics Inc.] Press Release Researcher Gets $2.85 Million Grant to Discover Ways to Enhance Bone Strength and Prevent Fractures A $2.85 million National Institute of Arthritis and Musculoskeletal and Skin Diseases-funded study at IUPUI will advance understanding of how bone cells sense and respond to mechanical force, one of the cues the skeleton relies on to regulate its strength. [Indiana University] Press Release | |
| |
POLICY NEWSHow Estonia Blazed a Trail in Science Since it joined the European Union (EU) in 2004, Estonia has spent more than €1 billion in EU funds on modernizing its research base. It now boasts strengths in numerous fields, including ecology, molecular biology and genetics, and has built up extensive international research networks. [Nature News] Editorial Surprise! Shutdown also Disrupting U.S. Science Agencies that Aren’t Closed Many U.S. government scientists and federally funded researchers breathed a sigh of relief last month, after the partial shutdown of the U.S. government began. That’s because the budget impasse between Congress and President Donald Trump didn’t affect some of the largest federal research agencies, including the $39 billion National Institutes of Health (NIH) and the $35.6 billion Department of Energy (DOE). [ScienceInsider] Editorial
| |
EVENTSNEW 2nd London Stem Cell Network Symposium Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – MSC Research (University of Illinois at Chicago College of Medicine) PhD Positions – Cancer Biology (Institut Curie) Postdoctoral Training Fellow – Cancer Genomics (The Francis Crick Institute) Assistant Professor – Sarcoma & Skeletal-Related Malignancies (UC Davis School of Medicine) Postdoctoral Fellow – Stem Cell Biology (City of Hope) Research Fellow – Stem Cell Biology (Brigham & Women’s Hospital – Harvard Medical School) Post Doctoral Fellow – Stem Cell Biology (Technion – Israel Institute of Technology) Assistant Professor – Cancer Biology (University of Pennsylvania Perelman School of Medicine) Assistant Professor Positions – Department of Cardiology (Boston Children’s Hospital) Assistant Professor – Department of Biological Sciences (Rutgers University Newark) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|